[1] [2] The discovery of exendin-4 in the 1990s revolutionised diabetes treatment by demonstrating that GLP-1 receptor agonism could effectively lower blood glucose levels whilst promoting weight loss
The FDA has not approved compounded versions of these drugs, and such products may carry safety, quality, and effectiveness risks due to variations in formulation, incorrect ingredients, improper storage, or inaccurate dosing
In an asthma mouse model, the administration of liraglutide led to a reduction in the expression of IL-33 and a decline in the infiltration of eosinophils and ILC2s in lung tissue
There are also meal delivery programs specifically for weight loss
In 2021, three of the four U.S
384(26): 24912492." Accessed on April 3, 2024, at PubMed Central (PMC) - "J Nephrol Ther